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Abstract
Transdermal therapeutic systems (TTS) have numerous 
pharmacological benefits. Drug release, for example, is inde-
pendent of whether a patient is in a fed or a fasted state, and 
lower doses can be given as gastrointestinal and hepatic 
first-pass metabolism is avoided. In addition, inter- and intra-
patient variability is minimized as the release of the drug is 
mainly controlled by the system. This makes TTS interesting 
as alternative systems to the most common dosage form of 
oral tablets. The difficulty with the dermal administration 
route is transporting the drug through the skin, since the 
skin is an efficient barrier against foreign bodies. Various 
strategies have been reported in the literature of how drug 
penetration can be improved. Most of them, however, focus 
on overcoming the stratum corneum as the first (mechani-
cal) skin barrier. However, penetration is much more com-
plex, and the skin’s barrier function does not only depend on 
the stratum corneum; what has been underestimated is the 
second (biological) skin barrier formed of enzymes. Com-
pared to the stratum corneum, very little is known about 
these enzymes, e.g., which enzymes are present in the skin 
and where exactly they are localized. Hence, very few strate-
gies can be found for how to bypass or even use the skin 
enzyme barrier for TTS development. This review article pro-
vides an overview of the skin enzymes considered to be rel-
evant for the biotransformation of dermally applied drugs. 
Also, we discuss the use of dermal prodrugs and soft drugs 
and give the stereoselectivity of skin metabolism careful 
consideration. Finally, we provide suggestions on how to 
make use of the current knowledge about skin enzymes for 
rational TTS design. © 2019 S. Karger AG, Basel
1 Introduction
1.1 Transdermal Therapeutic System
A drug can be administered via various administration 
routes. The most common dosage form in pharma world-
wide is the single-dose oral tablet. Recently, there has 
been a trend towards alternative dosage forms and ad-
ministration routes. Especially the market share of trans-
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dermal therapeutic systems (TTS) has grown significant-
ly. In 2005, the global TTS market was valued at USD 3 
billion and a compound annual growth rate (CAGR) of 
12% was predicted [1]. Ten years later (in 2016), the pre-
dicted CAGR was confirmed: the TTS market value had 
increased 10-fold to USD 30 billion [2]. More than 50% 
of the total volume was generated in North and Latin 
America, followed by Europe with 30%, and Asia Pacific 
with 25%. The TTS market value continues to rise. The 
CAGR is predicted to reach 7.5% by 2024 [3].
One explanation for this tendency might be that TTS 
make use of a convenient route for drug administration. 
TTS are small and lightweight, have a high durability, and 
can be stored at room temperature. Also, no water or oth-
er supplies are needed for their use. Patients therefore 
show high compliance with TTS treatment [4]. From a 
pharmacological view, a TTS overcomes potential disad-
vantages of oral dosage forms and can therefore act as a 
good complement to single-dose tablets. For example, 
drug release is independent of whether a patient is in a fed 
or a fasted state. Also, in most cases, a lower drug dose can 
be given compared to oral dosage forms, as gastrointesti-
nal and hepatic first-pass metabolism is avoided. Con-
stant plasma drug concentrations are achieved, without 
the typical plasma concentration peaks after each tablet 
intake. In addition, inter- and intrapatient variability is 
minimized as the release of the drug is mainly controlled 
by the system. For these reasons, TTS are a good and 
promising addition to the standard dosage form of the 
tablet.
1.2 Penetration and Permeation of Dermally  
Applied Drugs
To better understand the penetration and permeation 
mechanisms of dermally applied drugs, it is important to 
first understand the physiological functions of the skin. 
Its main functions are (a) protection against invading 
pathogens and other foreign substances from the external 
environment and (b) retaining water and essential nutri-
ents. Both functions depend on a strong barrier function 
of the skin. Basically, the skin possesses two different bar-
riers: a physical and a biochemical barrier. A drug must 
overcome both barriers, whereas the skin cannot distin-
guish between good and bad foreign substances.
1.3 The Skin as a Highly Efficient Barrier
1.3.1 The Stratum Corneum as the First  
(Physical) Barrier
The stratum corneum (SC) is the outermost part of the 
human skin. Being in direct contact with the environ-
ment, the SC can be counted as the first barrier of the 
body. It generally consists of 10–15 layers of highly or-
dered corneocytes. In a dry state, the layers of the SC are 
around 10–15 μm thin, whereas in a hydrated state the 
corneocytes absorb water and the thickness of the SC in-
creases significantly to up to 40 µm. Lipids produced by 
keratinocytes cover the corneocytes. This lets the envi-
ronment of the SC alternate between hydrophilic and li-
pophilic [5]. Therefore, besides other properties, foreign 
substances particularly need a well-balanced lipophilic 
and hydrophilic profile to overcome this barrier.
1.3.2 Skin Enzymes as the Second  
(Biochemical) Barrier
Foreign substances not trapped by the first barrier can 
be biotransformed by enzymes of the viable epidermis 
and dermis. The metabolic process may increase the wa-
ter solubility of foreign substances to achieve an increased 
excretion and elimination rate. Biotransformation, there-
fore, may serve as an explanation for why efficient drugs 
show only a decreased or almost no effect after penetra-
tion [6]. With respect to the number of cells, the skin pos-
sesses a biotransformation activity of one-third of that of 
the liver. Therefore, the skin is an organ with a high en-
zyme activity, which is important to consider when de-
signing dermally administered drugs. Currently, how-
ever, little is known about skin metabolism.
1.4 Aim
This review article provides an overview of enzymes 
reported to be present in human skin. Enzymes consid-
ered to be highly relevant for the biotransformation of 
dermally applied drugs are highlighted and described in 
detail. Also, the use of skin prodrugs and soft drugs is dis-
cussed, and stereochemical considerations are provided. 
Suggestions are made on how to make use of the current 
knowledge about skin metabolism for rational dermal 
drug design.
2 Results
2.1 Why Does Biotransformation Occur in  
Human Skin?
Biotransformation in the skin has the aim to make 
penetrating foreign substances less active and more wa-
ter-soluble for better excretion and elimination. For this, 
the skin metabolizes foreign substances in two consecu-
tive phases: a functionalization phase and a conjugation 
phase. In the functionalization phase, a polar group is ei-
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ther generated or unmasked by oxidative, reductive or 
hydrolytic reactions. In the second phase, the so-called 
conjugation phase, small hydrophilic endogenous mole-
cules, e.g., glucuronic acid, sulphate or glycerine, are co-
valently attached. The reaction product will always have 
an increased molecular weight. Nevertheless, excretion is 
improved due to pronouncedly increased hydrophilicity.
It is well known that enzymatic biotransformation of 
foreign substances is most effective in the human liver. 
Preliminary investigations, however, have shown that 
both the types of enzymes and the enzyme activities are 
not directly transferable to the skin; thus, knowledge of 
skin metabolism has to be acquired separately. So far, lit-
tle is known and very little information is available. In the 
following, we list a selection of enzyme families. They 
have both been reported to be present in human skin and 
been shown to be considerably involved in the degrada-
tion of topically applied drugs.
2.1.1 Alcohol Dehydrogenase
In humans, 5 enzyme classes of the alcohol dehydro-
genase (ADH) family are known: ADH1 with subunits α, 
β and γ, ADH2, ADH3, ADH4 and ADH5 [7]. The most 
prominent representative of the ADH family is ADH1, 
catalysing the oxidation of primary and secondary ali-
phatic alcohols to aldehydes (Fig. 1).
The main aim of this biotransformation is the detoxi-
fication of penetrating foreign substances. Ethanol, for 
example, is detoxified by liver ADH1 to ethanal. How-
ever, also the opposite can occur; methanol is metabo-
lized by the identical enzyme to toxic formaldehyde. 
Hence, these two phenomena can also emerge after drug 
administration. Biotransformation can make drugs inac-
tive, more potent or even toxic. This fact makes the inves-
tigation of skin enzyme activities on drugs relevant.
ADH was found in both human keratinocytes and hair 
root cells [8]. ADH activity on various alcohols in human 
skin was compared in vitro on excised human skin via 
enzyme assays, and in vivo on 12 clinically normal sub-
jects via an acute patch test [9]. In vitro, enzyme activity 
was expressed by the amount of generated NADH (Fig. 1), 
and in vivo by the occurrence of erythema. The activity of 
ADH varied for the different alcohols. The biotransfor-
mation rate increased clearly with an increasing length of 
the carbon chain. For example, pentanol (C5) was 3 times 
more catalysed by ADH1 than ethanol (C2). In addition, 
with an increasing degree of branching, the biotransfor-
mation rate decreased. Hence, the biotransformation rate 
of alcohols depends on the length and degree of branch-
ing: an increasing length of the carbon chain and a de-
creasing degree of branching lead to higher metabolic 
biotransformation.
2.1.2 Flavin-Dependent Monooxygenase
Flavin-dependent monooxygenase (FMO) is the main 
enzyme class for oxidation [10]. In human skin, it has a 
high transcription level, even higher than that of the CYP 
family [11]. The main difference between the two is how 
oxidation proceeds; CYP uses an oxygenated haem pros-
thetic group, whereas FMO uses flavin adenine dinucleo-
tide for substrate oxidation. FMO mainly biotransforms 
amine-, sulphide-, phosphorus-, and other nucleophilic 
heteroatom-containing compounds (Fig. 2, 3).
In the human body, 5 isoforms exist. Which of the 5 
isoforms are expressed in skin is controversially reported. 
Hu et al. [12] found all 5 isoform transcripts in native hu-
man skin, whereas Jäckh et al. [13] only observed tran-
scription of FMO1 and FMO3. The presence of FMO3 
was confirmed also by Wilkin and Stewart [9], via immu-
noblot analysis. However, no FMO1 was detected. Com-
parable findings were reported by Vyas et al. [14]. Thus, 
so far, in human skin only the transcription of FMO3 
seems to be definitively proven. Using benzydamine as a 
model substrate, the activity of FMO enzymes was as-

































Fig. 1. Oxidation of aliphatic alcohol to aldehydes catalysed by al-
cohol dehydrogenase.
Fig. 2. N-oxidation of tertiary and secondary amines catalysed by 
flavin-dependent monooxygenase.
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sessed in microsomes of abdominal skin biopsies. FMO 
biotransformed benzydamine to benzydamine N-oxide 
with a high oxygenation activity level of 5 nmol/min/mg 
protein [15]. This value strengthens the assumption that 
FMO is involved as the main enzyme class in the oxygen-
ation of dermally applied drugs.
2.1.3 Aldehyde Dehydrogenase
Aldehyde dehydrogenase (ALDH) converts aldehydes 
into carboxylic acids (Fig.  4). Twelve classes of ALDH 
were found in the entire human body [16]. In excised hu-
man skin, only ALDH1 and ALDH3 were detected, by 
Western blot analysis and immunohistochemistry. 
ALDH1 has a high affinity for aldophosphamide and 
plays an important role in the detoxification of peroxide 
aldehydes. In contrast, ALDH3 preferentially oxidizes ar-
omatic aldehydes and medium-chain aliphatic aldehydes 
(fatty aldehydes). Compared to the activity of ALDH in 
the liver, its activity in skin is reported to be 22-fold low-
er [8]. In addition, variation in ALDH activity according 
to gender and/or anatomical site was reported. Besides 
these facts, only little is known about ALDH in skin.
2.1.4 Carboxylesterase
Carboxylesterase (CE) hydrolyses carbon esters by in-
tramolecular addition of water to an alcohol and acidic 
residue: carboxylic ester + H2O ⇌ alcohol + carboxylate. 
Alcohols are then further oxidized to aldehydes and the 
carboxylates conjugated in phase 2 of biotransformation. 
The CE family is organized into 5 classes [17]. In the hu-
man liver, the isoenzymes CE1 and CE2 were found [18, 
19]. In human skin, only the presence of the CE2 iso-
enzyme has so far been verified in human keratinocytes 
[20]. Besides the cytochrome P450 (CYP) enzymes, the 
CE enzyme family are one of the more rigorously inves-
tigated skin enzymes. This reflects the importance of this 
family for the biotransformation of dermally applied 
drugs and for detoxification of foreign substances.
CE activity has been assessed in homogenates of hu-
man keratinocytes using fluorescein diacetate as a model 
substrate [21]. A hydrolytic activity of 3.7 nmol/min/mg 
protein was measured. Using p-nitrophenyl acetate as a 
model substrate instead, a much higher hydrolytic activ-
ity was measured: 45 nmol/min/mg protein was hydro-
lysed in cytosolic human skin fractions [22], correspond-
ing to a 12-times higher hydrolytic activity.
Interindividual fluctuation of hydrolytic activity was 
determined in primary breast keratinocytes of skin do-
nors. Biotransformation of the model drug 4-methylum-
belliferone heptanoate distinctly varied from 10 to 32 
nmol/min/mg protein [23]. Therefore, there was a highly 
polymorphic CE expression. Using 4-methylumbellifer-
one acetate instead of the heptanoate, a much weaker hy-
drolysis rate of 0.5 nmol/min/mg protein was measured 
[24]. The only difference between the two molecules lies 
in their chain lengths (C2 and C7). In analogy to ADH, 
the molecule with the longer carbon chain length was bio-
transformed at a higher rate (Fig. 5).
2.1.5 Cytochrome P450
CYPs are the largest group of metabolizing enzymes in 



























Fig. 3. S-oxidation of sulphides to sulphones catalysed by flavin-
dependent monooxygenase.
Fig. 4. Oxidation of aldehydes to carboxylic acids catalysed by al-
dehyde dehydrogenase.
Fig. 5. Ester hydrolysis of 4-methylumbelliferone heptanoate and 
acetate to 4-methylumbelliferone catalysed by carboxylesterase.
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molecular oxygen onto penetrating substrates, generat-
ing alcohol and water (Fig. 6).
Expression of CYP appears to be polymorphic [10]. Its 
activity shows remarkable interindividual variability de-
pending on age, gender and the anatomical site of appli-
cation. Which of the CYP enzymes are present in human 
skin has still not been clarified; contradictory data were 
reported. Hu et al. [12] and Hayden et al. [25] both found 
CYP2D6, CYP2E1 and CYP3A4 transcription in native 
human skin. In contrast, CYP1A1/2 and CYP2C9 were 
only demonstrated by Hu et al. [12], and CYP1B1 and 
CYP2A6 only by Hayden et al. [25].
2.2 Where in the Skin Does Biotransformation  
Take Place?
To verify the location of biotransformation, the hydro-
lysis of prednisolone (PS) 21-acetate to PS was measured 
[26]. Excised human skin was either separated into epi-
dermis and dermis by immersing the skin in water at 
60  ° C or cut into 10-µm-thick slices after freezing.
The following hydrolytic activities were found: 
 − Whole skin: 0.69 nmol/min/mg protein/mm thickness
 − Dermis: 0.41 nmol/min/mg protein/mm thickness
 − Epidermis: 5.2 nmol/min/mg protein/mm thickness
Hydrolysis, therefore, was proven to occur mainly in the 
epidermis. Analysis of the skin slices allowed for a more 
precise localization: of the entire skin, the stratum basale 
showed the highest hydrolytic activity [26].
In that study, however, the skin was either heated or 
frozen during the investigation. Enzymes are thermola-
bile. Especially when heated above 40  ° C, enzymes suffer 
a considerable loss of activity. An elegant method for the 
investigation of the hydrolytic activity of the respective 
skin layers seems to be confocal laser scanning examina-
tion. With this method, activity localization is possible 
without having to separate the skin into layers by heating 
or freezing. Fluorescein-5-isothiocyanate diacetate is ap-
plied to excised human skin and allowed to penetrate. If 
esterase enzymes are present, hydrolysis occurs and the 
green fluorescent fluorescein-5-isothiocyanate is re-
leased. This reaction product can then be visualized by 
confocal laser scanning. Only the viable epidermis emit-
ted a green glow, indicating that the viable epidermis is 
the most enzymatically active part of the skin [27].
The disadvantage of both abovementioned methods is 
the need for a model substance. As mentioned in the pre-
vious section, the activity of an enzyme is substance spe-
cific. Also, in both cases, only the enzymes possessing 
 hydrolytic activity were investigated. One method that 
avoids using a model substance and represents the activ-
ity of all enzymes is the measurement of oxygen con-
sumption. It has been assumed that oxygen consumption 
is proportional to the enzyme activity of cells. The viable 
epidermis showed the highest oxygen consumption at 
4.53 ± 1.39 µL O2/mg/h. At a far lower level, the dermis 
consumed 0.49 ± 0.12 µL O2/mg/h, which is only about 
one-tenth of the oxygen consumption of the viable epi-
dermis under identical conditions [28].
No matter how different the three methods are, they 
all lead to the same conclusion: the viable epidermis is the 
main location of biotransformation. The dermis also 
shows enzymatic activity, but it is much weaker than that 
of the epidermis. In addition, in the dermis the residence 
time of drugs is usually short, due to uptake into the sys-
temic circulation by capillaries. In sum, relevant drug bio-
transformation takes place almost exclusively in the via-
ble epidermis.
2.3 Factors Influencing the Enzymatic Activity  
of the Skin
2.3.1 Age
Esterase enzymes, mainly located in the keratinocytes 
of the skin, play an important role in skin metabolism. 
Therefore, the development and growth processes of ke-
ratinocytes are directly connected to its esterase activity. 
Ngawhirunpat et al. [29] found that when growing kera-
tinocytes, esterase enzymes are also increased. The bio-
transformation capacity of skin is age related. This should 
be considered when highly metabolized drugs are applied 
dermally, since on children, usually no clinical data are 
collected for dose recommendations; evaluated and well-
known doses for adults are often simply reduced accord-
ing to the weight of the child. For drugs highly metabo-
lized in skin, this method for dose adjustment cannot be 
recommended.
2.3.2 Anatomical Site and Gender
Even though the skin is considered as one organ, the 
requirements for each part of the skin are different. As a 
result, some enzymes are only found in specific regions of 
the body. The most prominent example is hydrocortisone 
+    2 e–    +    2 H+    +    O2
H
R +    H2O
OH
R
Fig. 6. Cytochrome P450-catalysed transfer of one oxygen atom 
resulting in alcohol and water.
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5α-reductase; activities of this enzyme were only found in 
the foreskin and scrotal skin [30]. Thus, this example also 
reveals a gender-specific expression of skin enzymes. No 
further literature was found dealing with the gender-spe-
cific activities of skin enzymes. However, sex differences 
found in hepatic metabolism suggest that differences may 
also exist in skin metabolism.
2.3.3 Environmental Factors
The activity of liver enzymes is well known to be de-
pendent on external factors. Skin enzymes also show this 
property. Environmental factors widely described in the 
literature as influencing enzyme activity are UV radiation 
and exposure to air pollution. UV radiation itself does not 
activate or inactivate enzymes, but it generates reactive 
oxygen species. An increased level of reactive oxygen spe-
cies, for example, leads to the suppression of matrix me-
tallopeptidase inhibitors, and thereby to increased MMP 
activity in the skin [31]. Further examples of UV radia-
tion-inducible enzymes in the skin are the two CYP en-
zymes CYP1A1 and CYP1B1 (see Section 2.1.5) [32], 
haem oxygenase [33, 34], cyclooxygenase [33, 35] and 
 nitric oxide synthase [36].
Furthermore, modification of the skin enzyme level by 
air pollution has been discussed in the literature. On the 
surface of particulate matter, polycyclic hydrocarbons are 
located. When particulate matter adheres to skin, pene-
tration of these polycyclic hydrocarbons is possible to a 
higher degree. Skin metabolizes these harmful molecules 
by benzo[a]pyrene hydroxylase. Increases in the amount 
and duration of exposure to polycyclic hydrocarbons on 
skin led to adjustment of the benzo[a]pyrene hydroxylase 
level [37].
It is evident that enzyme levels are modified not only 
by environmental molecules such as polycyclic hydrocar-
bons, but also by purposely applied compounds such as 
drugs in polymedicated patients. It is therefore advisable 
to also check drug interactions at the enzymatic level be-
fore prescription.
2.4 The Use of Animal Skin for the Prediction of 
Human Skin Metabolism
Excised human skin is rare, and the number of skin do-
nators is often not sufficient for representative studies; 
therefore, animal skin is commonly used instead. The re-
sults obtained in this way are extrapolated to predict the 
penetration and permeation of drugs in human skin. Rit-
tirod et al. [38] compared the permeation and metabolism 
of ethyl nicotinate (EN) to nicotinic acid (NA) in the skin 
of humans, rats, hairless rats, mice and hairless mice (Fig. 7).
Clear differences were found between the tested spe-
cies, due to the varying esterase activity. In human skin, 
an EN flux of 6.9 µmol/cm2/h and an NA flux of 1.6 µmol/
cm2/h were measured. This corresponded most closely to 
the values for murine skin with an EN flux of 5.3 µmol/
cm2/h and an NA flux of 1.6 µmol/cm2/h. In contrast, the 
greatest difference in metabolism was found in rat skin, 
with an EN flux of 0.4 µmol/cm2/h and an NA flux of 6.0 
µmol/cm2/h. The ratio of EN to NA remarkably decreas-
es from 4.3 for human skin to 0.07 for rat skin. Therefore, 
Rittirod et al. [38] suggested considering the species-de-
pendent skin enzyme activity when predicting the skin 
permeability for human skin from an animal model.
3 Discussion
3.1 How Can Skin Metabolism Be Used for Dermal 
Drug Design?
3.1.1 The Concept of the Prodrug
Prodrugs are pharmacologically inactive derivates of 
parent drugs. After entering the viable epidermis, en-
zymes biotransform prodrugs into the respective phar-
macologically active parent drugs. Prodrugs are formed 
when parent drugs possess unfavourable physicochemi-
cal properties for skin penetration. The final aim of the 
use of a prodrug always is an improvement of the parent 
drug’s bioavailability. Until now, only dermal products 
have been formed that release the parent drug after hy-
drolytic cleavage by phase I esterases. In the following, a 
few examples of prodrugs are given.
3.1.1.1 Ethyl Nicotinate → Nicotinic Acid. Metabolism 
of EN to NA was already presented in Section 2.4 to better 
understand the species-dependent drug penetration and 
metabolism. NA is too hydrophilic to efficiently penetrate 
the SC. By ethylating the alcoholic group of NA, lipophi-
licity distinctly increases. The logP value increases from 









Fig. 7. Cleavage of the prodrug ethyl nicotinate to the parent drug 
nicotinic acid.
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g/L for NA and EN, respectively [39, 40]. This example 
illustrates well how strongly the masking of a hydrophilic 
alcohol group affects the physicochemical properties of a 
drug.
3.1.1.2 N-Acyl Derivate → 5-Fluorouracil. 5-Fluoro-
uracil (5-FU) is a medication for the treatment of cancer. 
Dermally, 5-FU is applied for the treatment of actinic ker-
atosis and basal cell carcinoma. Due to the high hydro-
philicity of 5-FU, the principle of formulating a more li-
pophilic prodrug was applied. Nevertheless, this example 
differs, as a nitrogen group was masked instead of an al-
cohol group. Beall and Sloan [41] worked on two series of 
prodrugs: the alkyloxycarbonyl and the alkylcarbonyl se-
ries. Within each group, the prodrugs differed in the car-
bon chain length added to the parent drug. The rate of 
total delivered 5-FU through hairless murine skin was 
measured. All prodrugs delivered the parent drug more 
efficiently through skin, but the type of prodrug strongly 
affected the delivered amount of 5-FU: use of the alkyl-
carbonyl series resulted in far higher amounts of 5-FU. In 
addition, the carbon chain length played an important 
role: more 5-FU was detected with shorter carbon chains. 
For example, the 5-FU concentration measured was 40 
times higher with C1, 20 times higher with C2 and 4 times 
higher with C6.
3.1.1.3 N,N′-Bis-Acyl Derivate → 5-Fluorouracil. In a 
second step, Beall and Sloan [42] masked both nitrogen 
groups of 5-FU. Based on the results of the preliminary 
investigations, only the 1,3-bis-alkylcarbonyl prodrugs 
were investigated, and the carbon chain lengths from C1 
to C4 were used. Also for the 1,3-bis-alkylcarbonyl pro-
drugs, the highest delivery of 5-FU was detected with C1: 
the 5-FU concentration increased 5-fold. Thus, masking 
of both nitrogens was not beneficial when compared to 
the 40-fold increase in 5-FU delivery with the C1 N-alkyl-
carbonyl prodrug. What remained the same was the de-
crease in the delivered 5-FU amount with the increasing 
length of the carbon chain. Altogether, Beall and Sloan 
[42] did not recommend masking both hydrophilic 
groups when designing a prodrug of 5-FU.
3.1.1.4 Prednicarbate → 17- and 21-Ethyl Carbonate → 
Prednisolone. Prednicarbate (PC) can be used as a coun-
terexample to the 1,3-bis-alkylcarbonyl prodrugs of 5-FU. 
This doubly masked prodrug can be sufficiently biotrans-
formed by skin enzymes. Via two possible intermediates 
(17- and 21-ethyl carbonate), the parent drug PS is re-
leased in skin (Fig. 8). In excised human skin, esteratic 
OC cleavage proved dominant in the keratinocytes of vi-
able skin [21]. After 6 h of exposure, 12% PS had perme-
ated the skin. After 24 h of exposure, almost 83% of the 
applied PC was biotransformed. In tissue, the parent drug 
PS had the strongest presence, followed by 17-ethyl car-
bonate. Both PC and 21-ethyl carbonate were detected to 
a minor extent. In medium, only the parent drug PS was 
predominant. The amounts of 17- and 21-ethyl carbonate 
were comparable. The prodrug had by far the lowest pres-
ence. These values prove that skin enzymes can sufficient-
ly biotransform both masked alcohol groups of the pro-
drug PC. Why PS is completely hydrolysed can possibly 
be explained by the special spatial structure of PS. The 
androstane skeleton may be considered a plane, and the 
side chains rise almost vertically out of this plane. The 
side chains are arranged in the opposite direction. The 
side chain on position 17 is directed down and that on 
position 21 is directed up; thus, both are sterically freely 
available to enzymes on each side.
3.1.2 The Concept of the Soft Drug
The use of soft drugs is a novel approach to the design 
of safer drugs for local skin therapy. In contrast to pro-
drugs, soft drugs are per se active. In the viable epidermis 
and dermis, skin enzymes biotransform them into inac-
tive metabolites. The active drug, therefore, does not en-
ter the systemic circulation and the pharmacological ef-
fect is limited to the application area. While designing soft 
drugs, considerations regarding their biotransformation 
are integrated. This rational design of rapidly and pre-
dictably inactivated soft drugs can be used conversely to 
create drugs resisting biotransformation via skin en-
zymes.
3.1.2.1 Benzoyl Peroxide → Benzoic Acid (Fig. 9). Ben-
zoyl peroxide (BPO) was dermally applied to 5 patients 
for the treatment of leg ulcers [43]. Instead of BPO, only 
benzoic acid was detected in the patients’ serum. These 
findings show that BPO is completely metabolized in the 













Fig. 8. Cleavage of the prodrug prednicarbate via two possible in-
termediates (17- and 21-ethyl carbonate) to the parent drug pred-
nisolone.
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a systemically toxic effect of BPO in local therapy. BPO 
proved to have a strong affinity for enzymatic cleavage. 
One explanation for this could be that peroxides have an 
electron-enriched molecule section. This may make them 
more vulnerable to enzymatic attacks. Consequently, 
electron-rich or -poor domains should be avoided when 
designing metabolism-resistant drugs.
3.1.2.2 Fluocortin 21-Butylate → Fluocortin (Fig. 10). 
Fluocortin 21-butylate, a synthetic glucocorticoid corti-
costeroid, is marketed in European countries for the 
treatment of skin diseases such as dermatosis, dermatitis, 
eczema, erythema, first-degree burns and insect bites. In 
analogy to PC, its androstane skeleton is arranged in a 
plane. The butyl ester is almost perpendicular to the 
plane, and therefore freely accessible for the skin’s en-
zymes. The example of fluocortin 21-butylate demon-
strates well that stereochemistry plays an important role 
in enzymatic degradation. For the design of TTS drugs, 
possible hydrolysable molecular sections should be ar-
ranged less sterically accessible.
3.1.3 Is There Any Stereoselective Biotransformation?
3.1.3.1 Racemic Ketoprofen Ethyl Ester → (R)- and (S)-
Ketoprofen. Studies performed on HaCaT cells delivered 
results comparable to those with excised human skin re-
garding their biotransformation activity [21]. Ketoprofen 
is an NSAID used against pain and inflammation. (R)-
Ketoprofen has mostly analgesic properties, whereas (S)-
ketoprofen has 100- to 1,000-fold stronger anti-inflam-
matory characteristics. When orally administered, gas-
trointestinal side effects have frequently been reported, 
which is why transdermal application of ketoprofen has 
become more interesting. However, ketoprofen has phys-
iochemical properties that are unsuitable for the trans-
dermal route. Ketoprofen was formulated as a more lipo-
philic prodrug, ketoprofen ethyl ester (KEE). Both pene-
tration and metabolism were investigated in HaCaT cells. 
The results showed that CE2 is mainly responsible for the 
biotransformation of KEE into ketoprofen. Suppression 
of CE2 selectively inhibited the hydrolysis of KEE almost 
completely [44] (Fig. 11). Although racemic KEE was ap-
plied to the HaCaT cells, almost exclusively the R-KEE 
was transformed into (R)-ketoprofen. For a dermal prod-
uct with R/S-KEE as a prodrug, an analgesic but no anti-
inflammatory effect can be expected.
3.1.3.2 Diastereomeric Propranolol Ester → Propranolol 
(Fig. 12). Propranolol is an effective β-blocker. (S)-Pro-
pranolol is 100 times more potent than (R)-propranolol. 
Nonetheless, due to the distinct hepatic first-pass metabo-
lism of propranolol, its oral bioavailability is poor. For 
dermal delivery, propranolol is too hydrophilic. Thus, 
Udata et al. [45] synthesized a more lipophilic ester pro-
drug. Due to 2 chirality centres in the prodrug’s molecule, 
4 enantiomers exist (1S2S, 1S2R, 1R2R and 1R2S). De-
pending on their stereochemistry, their metabolism and 
flux into skin was evaluated. No stereospecific permeation 
in human skin was observed for racemic propranolol; 
both (S)- and (R)-propranolol permeated skin equally. In 
human skin tissue homogenates, the hydrolysis rates of 
the 4 enantiomers were different: 1S2R > 1R2R > 1R2S > 
1S2S. These results are well in agreement with other inves-
tigations; here too, hydrolysis was more pronounced with 
the 2R enantiomers. An important new finding was that 
the flux rates were different between the 4 enantiomers; 
this shows the dependence of skin penetration on a drug’s 
stereochemistry. In this study, the highest flux was ob-
tained with the 1S2S enantiomer, being 30-fold higher 
than that of the parent drug. On the other hand, this en-
antiomer is metabolized most weakly to the parent drug. 
The question remains as to which of the 4 enantiomers 
provides the highest (S)-propranolol concentration in the 










Fig. 9. Cleavage of the active drug benzoyl peroxide to inactive 












Fig. 10. Cleavage of the active drug fluocortin 21-butylate to inac-
tive fluocortin.
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4 Conclusions
There are few recent publications that investigate skin 
enzymes’ metabolizing activities affecting drug penetra-
tion and drug uptake. Since the types and activities of 
these enzymes are not comparable to those in other or-
gans (e.g., the liver), more skin-specific research in this 
area is needed in order to draw any clear and firm conclu-
sions. In addition, the fact that some metabolic processes 
are described in a controversial fashion makes it even 
more difficult to draw conclusions. However, we found 
enough similarities in these publications to allow us to 
make the following general recommendations. These rec-
ommendations will be useful for designing dermal drugs, 
since they pay attention to the issue of skin metabolism.
1. The types of skin enzyme vary with anatomical site and 
gender. Therefore, intra- and interindividual fluctua-
tions can occur, especially if the drug is extensively me-
tabolized.
2. Skin enzyme activity depends on age, becoming high-
er with increasing age. Thus, when using highly me-
tabolized drugs in children, their doses should not 
only be reduced based on the child’s weight.
3. By far the highest enzyme activity has been shown for 
the viable epidermis. Therefore, it is possible to effec-
tively use both dermal prodrugs and dermal soft drugs, 
since both become activated or inactivated before en-
tering the dermis, and thus before their systemic up-
take.
4. The geometric properties of chiral drugs are main-
tained after their biotransformation. This allows uti-
lizing the more active enantiomer when formulating 
prodrugs. If both enantiomers (R and S) are equally 
active, the R enantiomer can be used if high biotrans-
formation is required (e.g., prodrugs and soft drugs), 
and the S enantiomer if the applied drug should be 
degraded to a lesser extent by the enzymes of the 
skin.
5. When using these prodrugs and soft drugs, thought 
should be given to enzyme activity saturation. Esteri-
fication of more than one hydroxyl group (to obtain a 
more lipophilic prodrug) often leads to a lower release 
of the parent drug because the sterically more acces-
sible esters or ethers are cleaved first.
6. Instead of masking several hydroxyl groups, the car-
bon chain length may be varied to increase lipophilic-
ity. In most cases, enzymatic biotransformation was 
enhanced with increasing carbon chain lengths. In ad-
dition, aliphatic groups should not be branched if high 
biotransformation is desired. Here again, steric hin-
















Fig. 12. Cleavage of diastereomeric propranolol ester to “monoste-
reomeric” propranolol.


















Fig. 11. Stereoselective cleavage of racemic 
ketoprofen ethyl ester primarily to (R)-ke-
toprofen.
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